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http://dx.doi.org/10.1016/j.ccell.2014.09.001SUMMARYHedgehog (Hh) pathway inhibitors are clinically effective in treatment of basal cell carcinoma and medullo-
blastoma, but fail therapeutically or accelerate progression in treatment of endodermally derived colon and
pancreatic cancers. In bladder, another organ of endodermal origin, we find that despite its initial presence
in the cancer cell of origin Sonic hedgehog (Shh) expression is invariably lost during progression to invasive
urothelial carcinoma. Genetic blockade of stromal response to Shh furthermore dramatically accelerates
progression and decreases survival time. This cancer-restraining effect of Hh pathway activity is associated
with stromal expression of BMP signals, which stimulate urothelial differentiation. Progression is dramatically
reduced by pharmacological activation of BMP pathway activity with low-dose FK506, suggesting an
approach to management of human bladder cancer.INTRODUCTION
Postnatal Hedgehog (Hh) signaling functions in regulation of
stem cell physiology and tissue regeneration (Ahn and Joyner,
2005; Lai et al., 2003; Palma et al., 2005; Shin et al., 2011; Taipale
and Beachy, 2001). Following bacterial injury of the bladder, for
example, Sonic hedgehog (Shh) produced in cells of the basal
urothelium elicits production of secreted factors from stromal
cells, which in turn stimulate proliferation and differentiation of
urothelial cells. This epithelial/stromal feedback leads to regen-
eration of the urothelium and restoration of its normal function.
In this regenerative response to murine urinary tract infection,Significance
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These Shh-expressing basal stem cells also give rise to inva-
sive urothelial carcinoma in a murine chemical carcinogenesis
model utilizing the procarcinogen N-butyl-N-4-hydroxybutyl nit-
rosamine (BBN) (Shin et al., 2011, 2014). Nitrosamines are potent
carcinogens present in cigarette smoke, the most important risk
factor in human bladder cancer, and BBN specifically induces
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Figure 1. Absence ofSonic HedgehogExpression inHuman Invasive
Bladder Carcinoma
(A) Real time quantitative PCR measurement of SHH expression in benign
urothelium and invasive urothelial carcinoma tissues. Data are presented as
mean ± SEM, n = 3 technical replicates for each independent sample.
(B) Benign human urothelium immunostained for Shh and counterstained with
hematoxylin. Arrowheads in the boxed area enlarged on the right indicate
nonspecific staining of dying cells being sloughed off into the lumen.
(C) Human invasive urothelial carcinoma samples from four patients immu-
nostained for Shh and counterstained with hematoxylin. Arrowheads indicate
regions of Shh reactivity within tumor vasculature. Scale bars represent 50 mm.
Sample numbers correspond to those in Table S1.
See also Figure S1 and Table S1.
Cancer Cell
Stromal Hh Response Blocks Bladder Cancer Invasionwork, murine exposure to BBN reliably induced a premalignant
lesion histologically indistinguishable from human urothelial car-
cinoma in situ (CIS) by 3–4 months of exposure, with invasive
carcinoma developing by 5–6 months (Shin et al., 2014). BBN
exposure thus provides a clinically relevant experimental model
of human bladder carcinogenesis with a defined course of522 Cancer Cell 26, 521–533, October 13, 2014 ª2014 Elsevier Inc.progression to invasive carcinoma, with no prior bias regarding
genetic pathway or cell type.
We found in this model that marking of Shh-expressing basal
cells invariably marks tumors, whereas ablation of these cells
decisively abrogates tumor formation. Surprisingly, although
this combination of positive and negative evidence clearly dem-
onstrates that basal urothelial stem cells expressing Shh are the
exclusive cell of origin for invasive bladder cancer, expression of
Shh is lost by the time invasive carcinomas are formed (Shin
et al., 2011, 2014). A possible explanation for this observation
is that loss of Shh expression may somehow promote tumor pro-
gression. This effect, however, would represent a novel protec-
tive role for Hh pathway activity, as mutational activation of the
Hh pathway is causative in the primary cells of basal cell carci-
noma and medulloblastoma (Hahn et al., 1996; Johnson et al.,
1996; Teglund and Toftga˚rd, 2010), and ligand-dependent
pathway activity in stroma has been thought to promote growth
of pancreatic cancer (Olive et al., 2009; Yauch et al., 2008). To
elucidate the role of Hh signaling in bladder carcinogenesis,
we have examined SHH expression and signaling in benign
and malignant human bladder and have investigated the role
and mechanism of Hh signaling in the murine BBN model.
RESULTS
Absence of Sonic Hedgehog Expression in Human
Invasive Urothelial Carcinoma
Having previously established the absence of Shh expression
in murine invasive urothelial carcinoma (Shin et al., 2014), we
compared the expression of SHH mRNA in human benign uro-
thelium to that in five muscle-invasive urothelial carcinoma sam-
ples, with histological confirmation by hematoxylin and eosin
(H&E) staining of tissue sections (Figure S1A available online,
patient information in Table S1). We found that all five invasive
carcinoma samples examined showed a marked decrease in
SHH expression (Figure 1A), consistent with our previous work
in murine invasive urothelial carcinoma. To confirm and extend
these results, we performed immunohistochemistry (IHC) for
the expression of Shh protein in additional human invasive uro-
thelial carcinoma samples using an antibody that specifically de-
tects Shh, as validated by IHC of embryonic murine tissues in
which the expression pattern of Shh is well established (Roelink
et al., 1995) (Figure S1B). We found high levels of Shh protein in
human benign bladder urothelium (Figures 1B and S1C), but little
if any detectable Shh in the primary cancer cells of all eight inva-
sive carcinomas examined (Figures 1C and S1C). We note that
although Shh immunoreactivity was absent in cells of the carci-
noma, it was present within the tumor vasculature, and this may
account for the low level of SHH mRNA detected in the carci-
noma samples by RT-PCR. In addition to SHH, we also found
a decrease in the expression of Hh pathway target genes GLI1
and PTCH1 in all five invasive carcinoma samples (Figure S1D)
indicating that Hh pathway activity is reduced in response to
the decreased expression of ligand.
Genetic Ablation of Hedgehog Response Accelerates
Bladder Carcinogenesis
Given the consistent absence of SHH expression in invasive
urothelial carcinoma, we tested the possibility that loss of Hh
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sponse Accelerates Bladder Carcinogenesis
(A) H&E stains of bladder sections frommice treated
with TM, then exposed to BBN for 3 months.
Magnified views (lower panels) of boxed regions
confirm the presence (Gli1CreER/WT;Smoflox/flox, mice
with homozygous loss of Smo) or absence
(Gli1CreER/WT;Smoflox/WT, heterozygouscontrolmice)
of invasive carcinoma. Scale bars represent 50 mm.
(B) Kaplan-Meier survival curve of Gli1CreER/WT;
Smoflox/flox andGli1CreER/WT;Smoflox/WTmice (n = 10
in each group) injected with TM, exposed to BBN,
and euthanized when they became morbidly ill. An-
imals with homozygous loss of Smo survived a
median of 140 days, as compared to 215 days for
Smo heterozygous control animals (p < 0.0001, as
determined by the log-rank test).
Cancer Cell
Stromal Hh Response Blocks Bladder Cancer Invasionsignaling may accelerate tumor growth and progression, using
exposure of mice to BBN in drinking water as a model of
bladder carcinogenesis with a defined course of progression
to invasive carcinoma. In this model, the use of chemical rather
than genetically induced carcinogenesis permits the unencum-
bered use of genetic methods to investigate the biology of the
tumor. We previously made use of genetic marking to establish
that the Shh-expressing basal stem cell is the cancer cell of
origin and to investigate the tissue dynamics of invasive bladder
cancer progression (Shin et al., 2011, 2014); here we use
genetic methods to probe the role of Hh signaling during
carcinogenesis.
As previously established, Shh expression occurs constitu-
tively in basal cells of the urothelium and response to the
signal, as manifested by expression of Gli1, is restricted to
stromal cells (Shin et al., 2011). To genetically inactivate
stromal Hh response, we injected tamoxifen (TM) into mice
expressing CreER under control of the Gli1 promoter and car-
rying homozygous floxed alleles of the essential Hh pathway
transductory component Smoothened (Smo) (Gli1CreER/WT;
Smoflox/flox). Ablation of Smo in this manner will block Hh
response in stromal cells undergoing Hh response under base-
line conditions, prior to BBN exposure. In mice thus treated,
we found that invasive carcinomas appeared as early as
3 months after initiation of BBN exposure (Figure 2A, right
panels), a time at which control animals were just beginning
to develop CIS-like lesions (Figure 2A, left panels). Further-
more, these mice survived a median of 140 days, as compared
to 215 days for Smo heterozygous control animals (Figure 2B),
indicating that wild-type (WT) Smo function confers a 53% sur-
vival benefit. Genetic ablation of Hh response in bladder
stroma thus significantly accelerates the progression of BBN-
induced bladder cancer.
This result suggests a possible basis for the prevalence of
invasive carcinomas lacking Shh expression: given that uniform
loss of Hh response throughout the stroma accelerates cancer
growth, it seems reasonable that loss of Shh expression from a
clone of premalignant cells in a CIS lesion may confer a local
growth advantage by reducing Hh pathway response in neigh-
boring stroma, ultimately leading to preferential expansion of
such clones of cells during progression to advanced invasive ur-
othelial carcinomas.CReduced Expression of Differentiation Factors in
Smoothened-Ablated Mice
The consistent loss or attenuation of Shh expression in the later
stages of tumor progression and the experimental acceleration
of tumor progression with genetic ablation of Smo function in
Hh-responsive stromal cells together suggest that secreted stro-
mal factors induced by Hh signaling restrain the formation of
aggressive tumors. To identify Hh-regulated molecular path-
ways involved in delaying tumor formation, we performed gene
expression profiling on bladder samples from Gli1CreER/WT;
Smoflox/flox and Gli1CreER/WT;Smoflox/WT mice. Following TM in-
jection, mice were exposed to BBN for 2 months prior to gene
expression analyses (Figure S2A). The 2-month time point was
chosen in order to detect molecular changes that are present
early in the tumor formation process, before overt histological
differences can be seen, as these early molecular changes are
likely to drive the cellular processes responsible for later pheno-
typic differences. Indeed, bladders from BBN-exposed mice of
both genotypes were histologically identical at this 2-month
time point (Figure S2B), and did not display differences in epithe-
lial:stromal cell ratios (Figure S2C) or in the density of vascular el-
ements (Figure S2D).
Comparison of the gene expression profiles revealed that 468
genes were at least 2-fold downregulated in bladder samples
from Gli1CreER/WT;Smoflox/flox mice exposed to BBN (p < 0.01);
gene ontology analysis indicated an enrichment of genes
involved in developmental processes and cell differentiation in
this list (Table S2). The apparent downregulation of cell differen-
tiation genes in TM-treated Gli1CreER/WT;Smoflox/flox mice sug-
gests the possibility that accelerated cancer progression with
loss of Hh pathway activity is due to decreased expression of
differentiation-promoting factors that may increase the pool of
primitive cells with the potential to progress to invasive carci-
noma. Supporting this hypothesis, we found that Uroplakin
gene expression, which is indicative of urothelial differentiation,
is significantly decreased in Smo-ablated mouse bladders (Fig-
ure S2E). As decreased Hh pathway activity, occurring in stroma,
must affect tumor-forming urothelial cells, we focused on those
cell differentiation genes (Table 1) that encode secreted proteins
involved in cell signaling (Figure 3A). Bone morphogenic protein
4 (Bmp4) and Bmp5 (Bragdon et al., 2011) are particularly of in-
terest because: (1) Bmp4 has been shown to promote terminalancer Cell 26, 521–533, October 13, 2014 ª2014 Elsevier Inc. 523
Table 1. Genes Downregulated in Gli1CreER/WT;Smoflox/flox Mouse Bladders, following 2 Months of N-butyl-N-4-hydroxybutyl
Nitrosamine Treatment, Involved in Cell Differentiation—GO:0030154
Accession Number Symbol Gene Name Fold Change p Value
NM_007555 Bmp5 bone morphogenetic protein 5 8.0 1.59E-03
NM_027852 Rarres2 retinoic acid receptor responder (tazarotene induced) 2 6.5 1.31E-06
NM_024406 Fabp4 fatty acid binding protein 4 6.2 4.44E-03
NM_009605 Adipoq adiponectin, C1Q, and collagen domain containing 6.0 5.17E-05
NM_007554 Bmp4 bone morphogenetic protein 4 5.3 1.19E-04
NM_177708 Rtn4rl1 reticulon 4 receptor-like 1 5.0 4.92E-03
NM_001164035 Nft3 neurotrophin 3 4.8 2.38E-03
NM_009122 Satb1 special AT-rich sequence binding protein 1 4.0 6.07E-03
NM_031166 Id4 inhibitor of DNA binding 4 3.8 8.97E-03
NM_022984 Retn resistin 3.8 4.21E-03
NM_025943 Dzip1 DAZ interacting protein 1 3.7 1.35E-03
NM_173004 Cntn4 contactin 4 3.6 4.23E-03
NM_011255 Rbp4 retinol binding protein 4, plasma 3.6 8.99E-03
NM_001001309 Itga8 integrin alpha 8 3.6 1.11E-03
NM_009204 Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 3.6 9.72E-03
NM_009152 Sema3a sema domain, immunoglobulin domain, short basic domain,
secreted, (semaphorin) 3A
3.4 5.00E-03
NM_009365 Tgif1i1 transforming growth factor beta 1 induced transcript 1 3.4 1.75E-03
NM_001111027 Runx1t1 Runt-related transcription factor 1; translocated to, 1
(cyclin D-related)
3.4 2.46E-03
NM_172621 Clic5 chloride intracellular channel 5 3.4 1.91E-03
NM_175260 Myh10 myosin, heavy polypeptide 10, nonmuscle 3.2 6.48E-03
NM_015753 Zeb2 zinc finger E-box binding homeobox 2 3.1 2.77E-03
NM_008086 Gas1 growth arrest specific 1 3.1 8.17E-05
NM_010681 Lama4 laminin, alpha 4 3.1 3.14E-03
NM_027280 Nkd1 naked cuticle 1 homolog (Drosophila) 3.1 7.01E-03
NM_010518 Igfbp5 insulin-like growth factor binding protein 5 3.0 3.68E-03
NM_021339 Cdon cell adhesion molecule-related/downregulated by oncogenes 2.9 3.60E-03
NM_025282 Mef2c myocyte enhancer factor 2C 2.8 5.03E-03
NM_010280 Gfra3 glial cell line derived neurotrophic factor family receptor alpha 3 2.8 8.04E-04
NM_177089 Tacc1 transforming, acidic coiled-coil containing protein 1 2.7 2.76E-03
NM_001081106 Cytl1 cytokine-like 1 2.7 1.88E-04
NM_001102400 Dab2 disabled homolog 2 (Drosophila) 2.7 4.71E-03
NM_011614 Tnfsf12 tumor necrosis factor (ligand) superfamily, member 12 2.6 2.49E-03
NM_025891 Smarcd3 SWI/SNF related, matrix associated, actin dependent regulator
of chromatin, subfamily d, member 3
2.6 8.69E-04
NM_011129 Sept4 septin 4 2.5 3.40E-03
NM_001083334 Bin1 bridging integrator 1 2.5 3.37E-03
NM_009153 Sema3b sema domain, immunoglobulin domain, short basic domain,
secreted, (semaphorin) 3B
2.2 4.37E-06
NM_172506 Boc biregional cell adhesion molecule-related/downregulated by
oncogenes (Cdon) binding protein
2.2 7.64E-03
NM_001159382 Gjc1 gap junction protein, gamma 1 2.2 1.50E-03
NM_023328 Agtpbp1 ATP/GTP binding protein 1 2.1 5.46E-03
NM_008493 Lep leptin 2.1 6.27E-03
NM_001085370 Speg SPEG complex locus 2.1 9.46E-03
NM_001198571 Abi2 Abl-interactor 2.0 4.28E-03
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Figure 3. Reduced Expression of Differentiation Factors in Smoothened-Ablated Mice
(A) Comparison of gene expression profiles revealed 468 genes downregulated by at least 2-fold in Gli1CreER/WT;Smoflox/flox as compared to Gli1CreER/WT;
Smoflox/WT bladder samples (p < 0.01). Gene ontology analysis indicated an enrichment of genes involved in cell differentiation. Additional functional annotation of
the downregulated genes showed enrichment in the SP and Protein Information Resource Keywords (SP_PIR_KEYWORD) ‘‘Signal’’ and ‘‘Secreted.’’ The Venn
diagram shows the number of overlapping genes in each of the three categories, with 12 genes that encode secreted proteins involved in cell signaling and
differentiation.
(B) Expression in bladders of Gli1CreER/WT;Smoflox/flox as compared to Gli1CreER/WT;Smoflox/WT mice of Bmp4 (16-fold decrease, p < 0.0001), Bmp5 (34-fold
decrease, p < 0.001), and Gli1 (3.2-fold decrease, p < 0.0001). Mice were injected with TM just prior to 2 months of BBN exposure.
(C and D) Expression in four bladders from BBN-exposed mice (6 months) with invasive carcinoma of Bmp4 (p < 0.001) and Bmp5 (p < 0.001) as compared to a
control bladder (Ctrl) with no BBN exposure. Data are presented as mean ± SEM, and significance was calculated by an unpaired Student’s t test. n = 3 technical
replicates, and the entire experiment was repeated three times.
See also Figure S2 and Table S2.
Cancer Cell
Stromal Hh Response Blocks Bladder Cancer Invasiondifferentiation of bladder urothelium (Mysorekar et al., 2009); (2)
some Bmp genes are known to be directly regulated by Hh
pathway activity (Kawai and Sugiura, 2001; Roberts et al.,
1995); and (3) Bmp signaling plays a role in the differentiation
of tissues in other organs such as lungs (Weaver et al., 1999)
and heart (Schultheiss et al., 1997).
To confirm decreased Bmp4 and Bmp5 expression, we
carried out quantitative RT-PCR with samples from the blad-
ders of TM-injected Gli1CreER/WT;Smoflox/flox and Gli1CreER/WT;
Smoflox/WT mice exposed to BBN for 2 months. Attenuation of
Hh pathway activity was verified by a reduction in the expression
of Gli1, a transcriptional target of the pathway, and this was
correlated with a sharp reduction in the levels of Bmp4 and
Bmp5 (Figure 3B). We further examined Bmp4 and Bmp5
mRNA in WT mice exposed to BBN for 6 months and found
that expression of Bmp4 and Bmp5was greatly reduced in inva-
sive carcinoma as compared to control bladders from mice
without exposure to BBN (Figures 3C and 3D). This was accom-
panied by a decrease in the expression of Hh target genes Gli1
and Ptch1 (Figure S2F) and Bmp target genes Id1, Id2, Id3,
and Cdkn1b (Figure S2G). These results suggest that decreasedCBmp expression resulting from loss of Hh signaling may account
for the accelerated rate of tumor progression observed in mice
with ablated Smo function (Figure 2A).
Stromal Hedgehog Response Regulates Expression of
Human BMP4 and BMP5 Genes
To determine whether Hh signaling regulates expression of
BMP4 and BMP5 in human bladder, we first examined the
expression of Hh pathway components in primary human
bladder fibroblasts and epithelial cells. Consistent with immuno-
staining for Shh using benign bladder sections (Figures 1B and
S1C), we found that SHH is expressed in primary cultures of hu-
man bladder urothelial cells (Figure S3A), consistent with our
findings in the mouse (Shin et al., 2011). To evaluate response
to the Hh signal, we treated cultured human bladder stromal
and urothelial cells with ShhN protein or with the chemical
pathway agonist SAG (Chen et al., 2002b). Hh pathway activa-
tion, as judged by an increase in GLI1 expression, only occurred
in cultured stromal cells (Figure 4A), and this effect was reversed
by addition of the pathway antagonist cyclopamine (Chen et al.,
2002a; Cooper et al., 1998), suggesting that Hh signaling inancer Cell 26, 521–533, October 13, 2014 ª2014 Elsevier Inc. 525
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Figure 4. Stromal Hedgehog Response Regulates Expression of Human BMP4 and BMP5 Genes
(A) Expression of GLI1 in primary human bladder stromal cells treated with SAG (5.4-fold increase, p < 0.001), ShhN (1.6-fold increase, p < 0.05), and ShhN +
cyclopamine (Cyc) (no statistically significant change) as compared to unstimulated Ctrl stromal cells or in primary human bladder urothelial cells as compared to
Ctrl urothelial cells (no statistically significant change with any treatment).
(B) BMP4 and BMP5 expression in primary human bladder stromal cells treated with SAG (BMP4: 5.8-fold increase, p < 0.001 and BMP5: 2-fold increase, p <
0.01), ShhN (BMP4: 3.9-fold increase, p < 0.001 and BMP5: 1.6-fold increase, p < 0.05), and ShhN + Cyc (no statistically significant change) as compared to
unstimulated Ctrl cells.
(C) Expression of BMP target gene ID1 in cells treatedwith BMP agonist FK506 as compared to the DMSOvehicle Ctrl (2.4-fold increase in urothelial cells, p < 0.01
and 2-fold increase in J82 urothelial carcinoma cells, p < 0.01) or as compared to cells treated with FK506 after preincubation with the BMP inhibitor LDN-193189
(LDN)(4.5-fold increase in urothelial cells, p < 0.0001 and 10-fold increase in J82 cells, p < 0.001).
(D) Expression of the urothelial differentiation marker UPK1B in cells treated with FK506 as compared to DMSO Ctrl (3.2-fold increase in urothelial cells, p < 0.01
and 2.3-fold increase in J82 cells, p < 0.01) or as compared to cells treated with FK506 after preincubation with LDN (2.7-fold increase in urothelial cells, p < 0.01
and 1.8-fold increase in J82 cells, p < 0.05).
(E) Expression in human invasive urothelial carcinoma as compared to benign bladder tissues of BMP4 (11-fold decrease, p < 0.001) and BMP5 (7-fold decrease,
p < 0.001). Data are presented as mean ± SEM, and significance was calculated by an unpaired Student’s t test. n = 3 technical replicates, and the entire
experiment was repeated three times.
See also Figure S3.
Cancer Cell
Stromal Hh Response Blocks Bladder Cancer Invasionhuman bladder mirrors that in the mouse, with epithelial expres-
sion of Hh ligand and signal response restricted to stroma (Shin
et al., 2011). Concomitant with the increase in GLI1mRNA upon
stimulation of the cultured human bladder stromal fibroblasts,
we noted an increase in levels of BMP4 and BMP5 transcripts
(Figure 4B). These data suggest that stromal cells in human
bladder, like those in the mouse, respond to Hh ligand stimula-
tion with increased transcription of BMP4 and BMP5.526 Cancer Cell 26, 521–533, October 13, 2014 ª2014 Elsevier Inc.As Bmp4 and Bmp5 secreted from stromal cells have the po-
tential to act on urothelium, we examined the response of human
urothelial cells and urothelial carcinoma cells to BMP pathway
activation. To pharmacologically activate the BMP pathway,
we selected FK506, a drug that has long been used in transplant
patients for its immunopsuppressive effects. FK506 binds
FKBP12 and inhibits calcineurin, thus preventing activation of
NFAT and transcription of cytokines essential for immune
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(A) Schematic diagram of experimental strategy used to analyze the effect of
BMP pathway activation on bladder cancer progression. Mice exposed to
BBN for 4 months were treated with the BMP agonist FK506 or a vehicle
control for a month with continued BBN exposure before histopathological
analysis of the bladders.
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particular interest here, we recently showed that FK506 also
causes dissociation of FKBP12 from Type 1 BMP receptors,
thus activating the BMP pathway; this occurs at concentrations
below those required for immunosuppression, and FK506 at
these lower doses has proven to be effective upon systemic
administration in animal models of pulmonary arterial hyperten-
sion, which is causally associated with a deficiency of BMP
pathway activity (Spiekerkoetter et al., 2013).
The treatment of cultured primary urothelial cells with FK506
induced expression of the BMP target gene ID1 (Miyazono and
Miyazawa, 2002; Miyazono et al., 2005; Samanta and Kessler,
2004); this activation was blocked by combined treatment with
FK506 and the potent and specific BMP inhibitor LDN-193189
(Figure 4C) (Cuny et al., 2008; Yu et al., 2008), thereby confirmingCin our system that FK506 acts via BMP pathway activation.
Treatment of cultured urothelial cells with FK506 also induced
expression of the uroplakin genes UPK1B, UPK2, and UPK3A,
indicative of urothelial cell differentiation and consistent with
the previously reported role of BMP pathway activity in promot-
ing urothelial differentiation in vivo (Mysorekar et al., 2009);
again, this differentiation-inducing effect of FK506 treatment
was blocked by combined treatment with LDN-193189 (Figures
4D and S3B). Similar results were obtained using the urothelial
carcinoma cell line J82 (O’Toole et al., 1978) (Figures 4C and 4D).
These findings suggest a reciprocal epithelial-stromal signal
feedback loop in which Shh secreted by the urothelium activates
Hh response in bladder stromal cells, resulting in stromal expres-
sion of BMP4 and BMP5, which in turn signal back to the urothe-
lium to induce differentiation. Loss of Shh expression in human
invasive carcinomas, as noted previously (Figure 1A), would
be expected to disrupt this signal feedback; this expectation
was confirmed by a dramatic reduction of BMP4 and BMP5
expression in human invasive urothelial carcinoma as compared
to benign bladder (Figure 4E), as well as a reduction in expres-
sion of BMP target genes ID1, ID2, ID3, ID4, and CDKN1B
(Figure S3C).
Pharmacological Activation of the Bone Morphogenic
Protein Pathway Impedes Tumor Progression
To investigate the role of Bmp pathway activity in bladder tumor
progression and to test the possibility that Bmp pathway activa-
tion might impede tumor progression by stimulating urothelial
differentiation, we exposed mice to BBN for 4 months, then initi-
ated treatment with FK506 for another month at concentrations
below those required for its immunosuppressant effects (Spie-
kerkoetter et al., 2013) while also continuing exposure to BBN
(Figure 5A). Bmp pathway activity in these mice was confirmed
by increased expression of Bmp pathway targets, whereas un-
changed expression of target genes in the calcineurin/NFAT
pathway indicates minimal immunosuppressive activity (Figures
S4A–S4C). We have previously noted that mice exposed to BBN
for 4 months develop premalignant lesions indistinguishable
from human CIS, but not invasive carcinoma, which requires
further BBN exposure (Shin et al., 2014). In our control group,
continuation of BBN exposure for a total of 5 months resulted
in the development of invasive carcinoma in seven of nine
mice. For the cohort of ten mice treated with FK506 during the
final month, however, no invasive carcinoma was observed (Fig-
ures 5B, 5C, and S4D), suggesting that activation of Bmp
pathway activity may impede progression if treatment occurs
prior to formation of invasive carcinoma.
Large-Scale Transcriptional Profiling Suggests Loss of
Sonic Hedgehog/BoneMorphogenic Protein Signaling in
Invasive Human Bladder Cancers
Consistent with our finding of a functional role for loss of Shh
expression in progression to invasive urothelial carcinoma, a
previous RT-PCR analysis of human urothelial carcinomas at
advanced stages also showed low or undetectable expression
of SHHmRNA (Thievessen et al., 2005). In addition, our analysis
(Figure 6) of data from recently published large-scale studies
of gene expression in human invasive carcinoma also supports
the loss of SHH and BMP signaling in invasive human urothelialancer Cell 26, 521–533, October 13, 2014 ª2014 Elsevier Inc. 527
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Stromal Hh Response Blocks Bladder Cancer Invasioncarcinoma (Cancer Genome Atlas Research Network, 2014;
Choi et al., 2014). In this work, most human muscle-invasive ur-
othelial carcinomas were subdivided into three major subtypes:
papillary, luminal, and basal (Cancer Genome Atlas Research
Network, 2014; Choi et al., 2014). Based on the level of expres-
sion of characteristic markers of basal versus luminal character,
the invasive urothelial carcinomas produced in our BBN model
are most similar to the basal subtype of human urothelial carci-
noma (Figure S5A), which is the most aggressive form of bladder
cancer and has a lower median overall survival than the other
subtypes (Choi et al., 2014).
As the The Cancer Genome Atlas (TCGA) study also contains
expression data for normal bladder, we can ask whether our
findings of reduced SHH expression in invasive carcinoma rela-
tive to benign tissue are confirmed in human samples. A potential
caveat of such a comparison is that the TCGA study only
required that tumor nuclei constitute at least 60% of all nuclei
in order for a sample to be included (Cancer Genome Atlas
Research Network, 2014), whereas we used carefully selected
samples exclusively containing tumor tissue in our study.
Contamination with adjacent SHH-expressing benign tissue
thus could confound conclusions from the TCGA data regarding
SHH expression. Indeed, we have found that contamination of
human invasive carcinoma samples with adjacent benign tissue
leads to detection of higher SHH expression (Figures S5B and
S5C).
We nevertheless found in the cluster 3 (basal) subtype of the
TCGA study, which closely resembles the carcinoma subtype
induced in our murine BBN model, that SHH mRNA was signifi-
cantly reduced (500–1,000-fold or more; p < 0.001), as were its
targets PTCH1, GLI1, HHIP, BMP4, BMP5, and the BMP targets
ID2, ID3, and ID4. Given the magnitude of reduced expression
for all these genes and the high degree of statistical significance
(p ranged from < 0.01 to <0.001), these human data for the most
aggressive basal subtype of invasive urothelial carcinoma (clus-
ter 3) are fully consistent with our findings in the murine BBN
model that loss of Hh expression and consequent decreased
expression of BMP signals and downstream targets are an
essential feature of urothelial carcinoma progression.
Expression of SHH, BMP, and their targets was also reduced
in the other three subtypes of human invasive urothelial carci-
noma, and statistical significance for these reductions was
achieved in six of nine, five of nine, and six of nine of the genes
analyzed for clusters 1, 2, and 4, respectively. The less uniform
significance of the TCGA data for reduced expression of SHH/
BMP genes in clusters 1, 2, and 4may be due to greater contam-
ination by benign epithelial tissues, whose presence could cause
underestimation of the loss of epithelial SHH and stromal BMP.
Such contamination likely is less of a factor for the more aggres-
sive basal subtype (cluster 3), which would be expected to yield
purer tumor samples due to faster growth and consequentFigure 6. Reduced Expression of Hedgehog and Bone Morphogenic P
Carcinoma as Compared to Normal Urothelium
RNA-seq data from TCGA database with annotation of samples based on publish
indicates log2-transformed fragments per kilobase of transcript per million mapp
2011). If no reads map to the corresponding gene (FPKM = 0), the y axis value is se
are presented as mean and 95% confidence interval; normal: n = 19, cluster 1: n
calculated by Student’s t test. See also Figure S5.
Ccrowding out of benign tissues. Alternatively, it may be possible
that expression of differentiation-associated biomarkers in some
luminal subtype carcinomas within clusters 1 and 2 may result
from development of invasive properties while retaining a partial
response to SHH/BMP.
A Model for Bladder Cancer Progression
Our observations together support the model schematized in
Figure 7, in which progression of CIS to invasive carcinoma is
triggered by loss of Hh signaling. Following formation of CIS,
the loss of Shh expression leads to decreased local expression
of Hh-inducible stromal differentiation factors (BMPs), resulting
in increased numbers of undifferentiated premalignant cells
with proliferative advantages. Once transformed, these cells
can then initiate focal invasive behavior, as they fail to elicit stro-
mal differentiation factors (BMPs) while maintaining proliferative
capacity. This proliferative advantage during progression to in-
vasion results in selection of Shh-negative invasive carcinoma.
This model is strongly supported by the observed loss of Shh
expression in both murine and human invasive urothelial carci-
nomas (Shin et al., 2014) (see Figure 1), and by the dramatically
accelerated progression to invasive urothelial carcinoma ob-
served with BBN exposure when stromal response to Shh
signaling is experimentally ablated (see Figure 2). The role of
BMPs as mediators of this effect is suggested by Shh-depen-
dent expression of BMP4 and BMP5 in both murine and human
stromal cells (Figures 3 and 4), and by the dramatically delayed
progression to invasive carcinoma upon treatment with a BMP
pathway agonist (Figure 5). We propose that this delay of pro-
gression is likely due to induction of urothelial cell differentiation
by BMP pathway activity (Mysorekar et al., 2009); such activity is
present in benign tissues and at early stages of tumor develop-
ment because of stromal response to Shh from the urothelium.
The local reduction or loss of this differentiation-inducing activity
upon expansion of a clone of cells with loss of urothelial Shh
expression might then permit tumor cells within a nascent micro-
invasion to continue to grow and advance, leading ultimately to
invasive carcinoma (Figure 7). Interestingly, the TCGA study re-
vealed that mutations of genes involved in epigenetic regulation
were highly enriched in invasive urothelial carcinomas (Cancer
Genome Atlas Research Network, 2014); these findings suggest
the possibility that increased epigenetic plasticity may facilitate
the loss of SHH expression during urothelial carcinoma
progression.
DISCUSSION
The discovery of cyclopamine and synthetic mimics as Hh inhib-
itors that act by binding the essential pathway component Smo
(Chen et al., 2002a, 2002b; Cooper et al., 1998; Incardona
et al., 1998) has led to the development of potent Smorotein Pathway Ligands and Targets in Human Samples of Invasive
ed TCGA clusters (Cancer Genome Atlas Research Network, 2014). The y axis
ed reads (FPKM) values normalized using the RSEM algorithm (Li and Dewey,
t to10. Note that for SHH, FPKM = 0 for 17/31 cluster 3 (basal) samples. Data
= 41, cluster 2: n = 42, cluster 3: n = 31, and cluster 4: n = 15; significance was
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Stromal Hh Response Blocks Bladder Cancer Invasionantagonists as therapeutic agents. One of these, Vismodegib,
has been approved by the Food and Drug Administration for sys-
temic use in patients with metastatic or locally advanced basal
cell carcinoma (Ruch and Kim, 2013; Sekulic et al., 2012; Tang
et al., 2012), and promising early results with this and other Hh in-
hibitors have been reported in clinical trials in medulloblastoma
(Rudin et al., 2009). Despite promising preclinical studies in
mice with xenografted or autochthonous tumors (Olive et al.,
2009; Yauch et al., 2008), however, these drugs have not shown
clinical benefit in trials of pancreatic, colon, or ovarian cancers
(Herter-Sprie et al., 2013; Kaye et al., 2012; Ruch and Kim,
2013) and in some cases clinical trials had to be halted due to
accelerated cancer progression (Herter-Sprie et al., 2013; Ruch
and Kim, 2013).
Several recent papers, published during initial review of this
manuscript, have indicated that stromal response to Hh signaling
restrains the growth of oncogenic Kras-driven pancreatic cancer
in mice (Lee et al., 2014; O¨zdemir et al., 2014; Rhim et al., 2014).
These findings are more consistent with the results of pancreatic
cancer clinical trials than the earlier preclinical studies, but do not
reveal the molecular and cellular basis for these stromal effects.
In addition, the reliance of these tumorigenesis models on
expression of oncogenic Kras,which is associatedwith induction
of Shh expression, leaves open the possibility that tumor-re-530 Cancer Cell 26, 521–533, October 13, 2014 ª2014 Elsevier Inc.straining effects of stromal Hh pathway response may be rele-
vant primarily in the context of specific oncogene activation.
Our findings suggest that the restraining effects of stromal Hh
response on cancer progression indeed may be more general
because we have identified the urinary bladder as another organ
of endodermal origin within which such an effect occurs. In addi-
tion, because the BBN-induced urothelial carcinoma model
does not incorporate any prior genetic bias, the cancer-restraining
effects of stromal Hh response apparently extend beyond Kras-
dependent carcinogenesis to include other genetic etiologies.
Our findings also identify Hh elicitation of differentiation-inducing
BMP signals as the mechanism by which stromal Hh response
restrains urothelial carcinoma progression; whether induction of
differentiation by BMP or by other secreted factors mediates the
tumor-restraining effect of Hh stromal response in pancreatic can-
cer and potentially other cancer types remains to be determined.
Although stromal response to Hh signaling in the context of the
bladder includes expression of Wnt and other signals that trigger
proliferation (Shin et al., 2011), our findings indicate that it is loss
of differentiation-inducing factors such as Bmp4 and Bmp5 that
is critical for cancer progression, raising the question as to the
circumstances under which stromal induction of differentiation
or proliferation may prevail as a critical factor. We know in
the bladder that balanced production of proliferation- and
Cancer Cell
Stromal Hh Response Blocks Bladder Cancer Invasiondifferentiation-inducing stromal signals is critical to regeneration
of normal urothelium (Shin et al., 2011), but it seems that during
cancer progression the differentiation-inducing activity becomes
critical to keeping the tumor in check. A possible explanation for
the heightened emphasis on differentiation factors is that cells of
nascent epithelial cancers may first acquire reduced depen-
dence on extracellular proliferative signals through genetic or
epigenetic changes that generate cell-autonomous proliferative
drive, while still leaving cells sensitive to the effects of stromal
differentiation-inducing factors. This stromal source of differen-
tiative drive may help confine proliferating cells to the epithelium,
with cancer progression triggered by loss of the production or of
the response to such stromal differentiation-inducing factors. If
epithelial Hh signals to stroma in other endodermal organs also
elicit balanced proliferative and differentiative responses, then
an understanding of the impact of Hh pathway activity may
require knowledge both of normal homeostasis aswell as the de-
rangements associated with carcinogenesis.
Finally, we note that our findings in urothelial carcinoma carry
several significant therapeutic implications. First, because stro-
mal Hh response may exert tumor-restraining effects in a wide
range of cancers that originate from endodermal organs, careful
evaluation and monitoring for the development of other malig-
nancies would be important in patients undergoing systemic
treatment with Hh pathway antagonists. Second, because
FK506 treatment produces therapeutic BMP pathway activation
at doses that cause minimal immunosuppression, such low-
dose FK506 treatment may have utility in treatment of cancers
arising from organs in which BMP pathway activity induces
cellular differentiation. In bladder cancer, although 70%–80%
of cases present as noninvasive, high rates of recurrence and
progression make treatment of this cancer more costly than
any other on a per patient basis (Sievert et al., 2009). The ability
to halt or slow progression by treatment with agents such as
FK506 thus could have a significant beneficial impact on the clin-
ical management of bladder cancer.
EXPERIMENTAL PROCEDURES
Mice
ForSmodeletion experiments,Gli1CreER/WTmicewerematedwith theSmoflox/flox
(Kimura et al., 2005; Long et al., 2001) strain to obtain Gli1CreER/WT;Smoflox/flox
and Gli1CreER/WT;Smoflox/WT mice, which were injected intraperitoneally with
4 mg of TM (per 30 g body weight) daily for three consecutive days prior to
BBN exposure. All mouse strains were obtained from Jackson Laboratories.
Male mice 8–10 weeks of age were used. For each experiment, mice in each
cage were randomly selected for drug/TM or control treatments. Mouse proce-
dures were performed under isoflurane anesthesia, which was administered in a
fume hood with a standard vaporizer (J.B. Baulch & Associates). All procedures
were performed under a protocol approved by the Administrative Panel on Lab-
oratory Animal Care at Stanford University.
N-butyl-N-4-hydroxybutyl Nitrosamine-Induced Bladder
Carcinogenesis
A 0.1% concentration of BBN (TCI America) was dissolved in drinking water,
and BBN-containing water was provided to mice ad libitum for 3–6 months
in a dark bottle. BBN-containing water was changed twice a week. Bladders
were collected and analyzed after 3 to 6 months of BBN administration.
Human Bladder Tissue Samples
Human bladder tissue samples were obtained from the Stanford Tissue Bank
or were collected under appropriate informed consent agreements approvedCby the Institutional Review Board at Stanford University. The bladder tissue
samples were obtained and processed within 1 hour after endoscopic resec-
tion or radical cystectomy from patients with confirmed muscle invasive uro-
thelial carcinoma (stageR pT2). For gene expression analysis, unfixed tissue
samples were embedded in optimal cutting temperature (OCT) compound
(Tissue-Tek) for snap freezing. For IHC, tissue samples were fixed in 4% para-
formaldehyde (PFA) overnight at 4C, followed by dehydrating in 30% sucrose
overnight then embedded in OCT compound, and sectioned into 12-micron
thick sections with a Microm cryostat.
Immunohistochemistry
Frozen sections of patient bladder tissue sampleswere air-dried for 20min and
postfixed in 4% PFA for 30 min. Sections were then blocked for endogenous
peroxidase activity for 10 min with BLOXALL (Vector Labs) and subsequently
incubated with 1.5% goat serum for 30 min, followed by incubation with pri-
mary rabbit anti-Shh antibody (C9C5, Cell Signaling) overnight. Sections
were then incubated with secondary biotinylated goat antirabbit antibody
(Vector Labs) for 60 min, followed by incubation with VECTSTAIN ABC Stan-
dard Kit (Rabbit IgG; Vector Labs) for 30 min. Sections were developed with
ImmPACT DAB peroxidase substrate (Vector Labs) for 1 min and counter-
stained with Hematoxylin QS (Vector Labs). Sections were gradually dehy-
drated and cleared before mounting with cytoseal 60 (Thermo Scientific).
Histological Analysis
Human or mouse tissue specimens were embedded in OCT compound and
sectioned into 12-micron thick sections with a Microm cryostat. Slides were
fixed in 4% PFA for 30 min at 4C, stained with hematoxylin, then counter-
stained with eosin. Histological assessment of bladder tissue sections was
blinded in order to ensure that the pathologist who assessed the tissues did
not know which treatment or patient group each sample belonged to.
Microarray Analysis
Gli1CreER/WT;Smoflox/flox and Gli1CreER/WT;Smoflox/WT mice were injected intra-
peritoneally with 4 mg of TM per 30 g body weight daily for three consecutive
days. BBN-containing water was provided to the mice ad libitum after the last
TM injection. After 2 months, the mice were sacrificed, bladders harvested,
and total RNA was prepared using the RNeasy Plus Mini Kit (QIAGEN). RNA
quality was evaluated using the Agilent 2100 Bioanalyzer system. Samples
were hybridized to the Affymetrix GeneChip Mouse Exon 1.0 ST microarray
chips. There were three mice of each genotype that were analyzed. After hy-
bridization, expression values were normalized using the robust multiarray
average function in the Partek Genomics Suite software. Differentially ex-
pressed genes were identified using ANOVA, genes showing a fold change
greater or equal to two with p value < 0.01 were shortlisted for functional anno-
tation analyses. Examination of overrepresented gene ontology terms and
Swiss-Prot (SP) and Protein Information Resource (PIR) Keywords (SP_PIR_
KEYWORDS) was performed using DAVID (Huang et al., 2007) (http://david.
abcc.ncifcrf.gov/), in which enrichment in annotation terms was measured
using a modified Fisher’s Exact test. A p value < 0.05 was regarded as signif-
icant. Expression changes detected by microarray analysis were validated by
verifying expression levels of several representative genes with quantitative
RT-PCR.
Quantitative RT-PCR
Bladder samples were snap frozen in liquid nitrogen, homogenized with a
mortar and pestle, and RNA extracted with the RNeasy Plus Mini kit (QIAGEN).
For quantitative RT-PCR of mRNA transcripts, first-strand cDNA was made
using the SuperScript III First-Strand Synthesis SuperMix (Invitrogen 18080-
400). Quantitative RT-PCR was performed using iQ SYBR Green Supermix
(Bio-Rad 170-8880) and the Bio-Rad iCycler, and gene expression was
normalized to the house-keeping gene HPRT1.
Immunofluorescence Analysis
Bladders were harvested frommice, fixed in 4%PFA, embedded in OCT com-
pound, and sectioned into 12-micron thick sections with a Microm cryostat.
Sections were blocked in goat serum and incubated with primary antibodies
(anti-SMA, Sigma 1A4, 1:1,000; anti-CD31, BD biosciences 550274, 1:500;
and anti-EpCAM, Developmental Studies Hybridoma Bank G8.8, 1:500)ancer Cell 26, 521–533, October 13, 2014 ª2014 Elsevier Inc. 531
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tibodies, and imaged with a confocal microscope. For quantification of epithe-
lial:stromal ratios, the total number of epithelial cells in each section, marked
by expression of EpCAM, were counted. The total number of stromal cells,
which are indicated by the nuclei present between the epithelial layer and
the muscular bladder wall, were also counted and the ratio of the total number
of epithelial cells to the total number of stromal cells in each tissue section
calculated. For quantification of vascular density, the number of CD31+ ves-
sels in four 403 fields of view per tissue section was counted and averaged
to obtain the mean vascular density.
Human Bladder Cell Culture
Primary human bladder urothelial cells (ScienCell 4320) and bladder stromal fi-
broblasts (ScienCell 4330) were cultured in Urothelial Cell Medium (ScienCell
4321) and Fibroblast Medium (ScienCell 2301), respectively to subconfluency.
Cells were then starved for 12 hr, followed by addition of Shh conditioned me-
dium in the absence or in the presence of cyclopamine (3 mM, Toronto
Research Chemicals), or treated with the Shh pathway agonist SAG (200 nM,
Millipore) for 24 hr. In separate experiments, primary human bladder urothelial
cells (ScienCell 4320) or J82 human urothelial carcinoma cells (American Type
Culture Collection HTB1) were pretreated with 120 nM LDN-193189 or DMSO
control (Selleckchem S2618) for 30 min prior to treatment with 20 ng/ml FK506
(Cayman Chemical) or treated with a DMSO control for 12 hr. Following treat-
ment, RNA was extracted using the Trizol reagent.
Pump Implantation
Alzet osmotic pumps (Alzet, no. 2004) were used to administer FK506
(Cayman Chemical) to mice at a dose of 0.05 mg per kilogram mouse body
weight per day. Each pump was filled with 200 ml of FK506, then implanted
subcutaneously into the back of each mouse, slightly posterior to the scap-
ulae, and the incision closed with wound clips.
Western Blotting
Control-treated or FK506-treatedmouse bladders were homogenized and sol-
ubilized in radio-immunoprecipitation assay buffer, followed by brief centrifu-
gation. Supernatants were utilized for SDS/PAGE and western blotting with
phosphorylated Smad1/5/8 (Cell Signaling #9511) and control b-Actin (Santa
Cruz sc-47778) antibodies. Densitometric analysis of western blot bands
was performed using Image J software (NIH).
Data Analysis
Statistical analysis was performed using GraphPad Prism software v.5. All
data are presented as mean ± SEM, and two group comparisons were done
with a two-tailed Student’s t test. A value of p < 0.05 was taken as statistically
significant. For analysis of TCGA data, we downloaded bladder cancer (BLCA,
Level 3) RNA-Seq data generated at University of North Carolina in IlluminaHi-
Seq_RNASeqV2 platform from the TCGA data portal. We annotated the data
with the published TCGA bladder cancer clusters and normal bladder urothe-
lium. We performed a t test to assess the significance.
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